Ellevest Inc. raised its holdings in Incyte Co. (NASDAQ:INCY – Free Report) by 52.6% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 548 shares of the biopharmaceutical company’s stock after purchasing an additional 189 shares during the quarter. Ellevest Inc.’s holdings in Incyte were worth $40,000 as of its most recent SEC filing.
Other institutional investors have also recently bought and sold shares of the company. Desjardins Global Asset Management Inc. increased its stake in shares of Incyte by 22.7% in the 4th quarter. Desjardins Global Asset Management Inc. now owns 687 shares of the biopharmaceutical company’s stock valued at $55,000 after buying an additional 127 shares during the period. 180 Wealth Advisors LLC increased its stake in shares of Incyte by 4.0% in the 4th quarter. 180 Wealth Advisors LLC now owns 3,613 shares of the biopharmaceutical company’s stock valued at $311,000 after buying an additional 139 shares during the period. Ontario Teachers Pension Plan Board increased its stake in shares of Incyte by 1.0% in the 4th quarter. Ontario Teachers Pension Plan Board now owns 14,555 shares of the biopharmaceutical company’s stock valued at $1,169,000 after buying an additional 149 shares during the period. D.A. Davidson & CO. increased its stake in shares of Incyte by 4.8% in the 1st quarter. D.A. Davidson & CO. now owns 3,300 shares of the biopharmaceutical company’s stock valued at $262,000 after buying an additional 150 shares during the period. Finally, China Universal Asset Management Co. Ltd. increased its stake in shares of Incyte by 8.5% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 2,260 shares of the biopharmaceutical company’s stock valued at $182,000 after buying an additional 177 shares during the period. Institutional investors own 97.53% of the company’s stock.
Wall Street Analyst Weigh In
INCY has been the subject of several research reports. Oppenheimer reissued an “outperform” rating and issued a $92.00 target price on shares of Incyte in a research note on Wednesday. Morgan Stanley reaffirmed an “equal weight” rating and set a $74.00 price objective on shares of Incyte in a research note on Wednesday. BMO Capital Markets decreased their price objective on Incyte from $70.00 to $68.00 and set a “market perform” rating for the company in a research note on Wednesday. Bank of America cut Incyte from a “buy” rating to a “neutral” rating and set a $84.00 price objective for the company. in a research note on Thursday, May 4th. Finally, Royal Bank of Canada lifted their price objective on Incyte from $70.00 to $73.00 and gave the stock a “sector perform” rating in a research note on Wednesday. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $82.00.
Incyte Stock Performance
Incyte Company Profile
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States, Europe, Japan, and internationally. The company offers JAKAFI (ruxolitinib), for the treatment of adults with intermediate or high-risk myelofibrosis; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia.
Recommended Stories
- Five stocks we like better than Incyte
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- MarketBeat Week in Review – 07/31 – 08/04
- What is a Mid Cap Stock? How to Invest
- 3 Best Meme ETFs to Buy Now
- How to Invest in Esports
- XPO Keeps Reaching New Highs: Markets Love the Stock
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.
